J. Krishnan, Kayley M Ancy, C. Oromendia, K. Hoffman, I. Easthausen, N. Leidy, M. Han, R. Bowler, S. Christenson, D. Couper, G. Criner, J. Curtis, M. Dransfield, N. Hansel, A. Iyer, R. Paine Iii, S. Peters, J. Wedzicha, P. Woodruff, K. Ballman, F. Martinez
{"title":"利用COPD问卷中呼吸道症状评价来表征COPD稳定状态下的症状变异性","authors":"J. Krishnan, Kayley M Ancy, C. Oromendia, K. Hoffman, I. Easthausen, N. Leidy, M. Han, R. Bowler, S. Christenson, D. Couper, G. Criner, J. Curtis, M. Dransfield, N. Hansel, A. Iyer, R. Paine Iii, S. Peters, J. Wedzicha, P. Woodruff, K. Ballman, F. Martinez","doi":"10.15326/jcopdf.2021.0263","DOIUrl":null,"url":null,"abstract":"Rationale\nIt has been suggested that patients with COPD experience considerable daily respiratory symptom fluctuation. A standardized measure is needed to quantify and understand the implications of day-to-day symptom variability.\n\n\nObjectives\nTo compare standard deviation with other statistical measures of symptom variability and identify characteristics of subjects with higher symptom variability.\n\n\nMethods\nIndividuals in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) Exacerbations sub-study completed an Evaluating Respiratory Symptoms in COPD (E-RS) daily questionnaire. We calculated within-subject standard deviation (WS-SD) for each patient at week 0 and correlated this with measurements obtained four weeks later using Pearson's r and Bland Altman plots. Median WS-SD value dichotomized participants into higher versus lower variability groups. Association between WS-SD and exacerbation risk during four follow up weeks was explored.\n\n\nMeasurements and Main Results\nDiary completion rates were sufficient in 140 (68%) of 205 sub-study participants. Reproducibility (r) of the WS-SD metric from baseline to week four was 0.32. Higher variability participants had higher St. George's Respiratory Questionnaire (SGRQ) scores (47.3 ± 20.3 vs 39.6 ± 21.5, p=.04) than lower variability participants. Exploratory analyses found no relationship between symptom variability and HCRU exacerbations.\n\n\nConclusions\nWS-SD of the E-RS can be used as a measure of symptom variability in studies of patients with COPD. Patients with higher variability have worse health-related quality of life. WS-SD should be further validated as a measure to understand the implications of symptom variability.","PeriodicalId":10249,"journal":{"name":"Chronic obstructive pulmonary diseases","volume":"75 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Questionnaire.\",\"authors\":\"J. Krishnan, Kayley M Ancy, C. Oromendia, K. Hoffman, I. Easthausen, N. Leidy, M. Han, R. Bowler, S. Christenson, D. Couper, G. Criner, J. Curtis, M. Dransfield, N. Hansel, A. Iyer, R. Paine Iii, S. Peters, J. Wedzicha, P. Woodruff, K. Ballman, F. Martinez\",\"doi\":\"10.15326/jcopdf.2021.0263\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rationale\\nIt has been suggested that patients with COPD experience considerable daily respiratory symptom fluctuation. A standardized measure is needed to quantify and understand the implications of day-to-day symptom variability.\\n\\n\\nObjectives\\nTo compare standard deviation with other statistical measures of symptom variability and identify characteristics of subjects with higher symptom variability.\\n\\n\\nMethods\\nIndividuals in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) Exacerbations sub-study completed an Evaluating Respiratory Symptoms in COPD (E-RS) daily questionnaire. We calculated within-subject standard deviation (WS-SD) for each patient at week 0 and correlated this with measurements obtained four weeks later using Pearson's r and Bland Altman plots. Median WS-SD value dichotomized participants into higher versus lower variability groups. Association between WS-SD and exacerbation risk during four follow up weeks was explored.\\n\\n\\nMeasurements and Main Results\\nDiary completion rates were sufficient in 140 (68%) of 205 sub-study participants. Reproducibility (r) of the WS-SD metric from baseline to week four was 0.32. Higher variability participants had higher St. George's Respiratory Questionnaire (SGRQ) scores (47.3 ± 20.3 vs 39.6 ± 21.5, p=.04) than lower variability participants. Exploratory analyses found no relationship between symptom variability and HCRU exacerbations.\\n\\n\\nConclusions\\nWS-SD of the E-RS can be used as a measure of symptom variability in studies of patients with COPD. Patients with higher variability have worse health-related quality of life. WS-SD should be further validated as a measure to understand the implications of symptom variability.\",\"PeriodicalId\":10249,\"journal\":{\"name\":\"Chronic obstructive pulmonary diseases\",\"volume\":\"75 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-04-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chronic obstructive pulmonary diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15326/jcopdf.2021.0263\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chronic obstructive pulmonary diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15326/jcopdf.2021.0263","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
有研究表明,慢性阻塞性肺病患者每日呼吸症状波动较大。需要一种标准化的措施来量化和理解日常症状变异性的含义。目的比较症状变异性的标准差与其他统计方法的差异,确定症状变异性较高的被试的特征。方法慢性阻塞性肺病研究(SPIROMICS)加重亚研究的亚群个体和中间结局指标完成了COPD呼吸症状评估(E-RS)每日问卷调查。我们计算了每个患者在第0周的受试者内标准差(WS-SD),并使用Pearson's r和Bland Altman图将其与四周后获得的测量结果相关联。WS-SD值中位数将参与者分为高变异性组和低变异性组。在4周的随访中探讨WS-SD与恶化风险的关系。在205个子研究参与者中,140人(68%)的日记完成率是足够的。WS-SD指标从基线到第4周的重现性(r)为0.32。高变异性受试者的圣乔治呼吸问卷(SGRQ)得分高于低变异性受试者(47.3±20.3 vs 39.6±21.5,p= 0.04)。探索性分析未发现症状变异性与HCRU恶化之间的关系。结论E-RS的sws - sd可作为COPD患者症状变异性的衡量指标。变异性较高的患者健康相关生活质量较差。应该进一步验证WS-SD作为一种度量,以了解症状可变性的含义。
Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Questionnaire.
Rationale
It has been suggested that patients with COPD experience considerable daily respiratory symptom fluctuation. A standardized measure is needed to quantify and understand the implications of day-to-day symptom variability.
Objectives
To compare standard deviation with other statistical measures of symptom variability and identify characteristics of subjects with higher symptom variability.
Methods
Individuals in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) Exacerbations sub-study completed an Evaluating Respiratory Symptoms in COPD (E-RS) daily questionnaire. We calculated within-subject standard deviation (WS-SD) for each patient at week 0 and correlated this with measurements obtained four weeks later using Pearson's r and Bland Altman plots. Median WS-SD value dichotomized participants into higher versus lower variability groups. Association between WS-SD and exacerbation risk during four follow up weeks was explored.
Measurements and Main Results
Diary completion rates were sufficient in 140 (68%) of 205 sub-study participants. Reproducibility (r) of the WS-SD metric from baseline to week four was 0.32. Higher variability participants had higher St. George's Respiratory Questionnaire (SGRQ) scores (47.3 ± 20.3 vs 39.6 ± 21.5, p=.04) than lower variability participants. Exploratory analyses found no relationship between symptom variability and HCRU exacerbations.
Conclusions
WS-SD of the E-RS can be used as a measure of symptom variability in studies of patients with COPD. Patients with higher variability have worse health-related quality of life. WS-SD should be further validated as a measure to understand the implications of symptom variability.